22 June 2023 - Preliminary clinical data demonstrated a robust immune response by the company's XBB.1.5 monovalent vaccine against XBB descendent lineage viruses.

Moderna today announced that it has completed submission of a regulatory application to the US FDA for its updated COVID-19 vaccine containing spike proteins for the XBB.1.5 sub-lineage of SARS-CoV-2 (mRNA-1273.815).

Read Moderna press release